Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Anti-obesity Pharmacotherapy and Inflammation
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-05-23
- Target Recruit Count
- 24
- Registration Number
- NCT05756764
- Locations
- 🇺🇸
Ochsner Health System - Biospecimen, New Orleans, Louisiana, United States
🇺🇸LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO, New Orleans, Louisiana, United States
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
- Conditions
- Interventions
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Matthew J. Budoff
- Target Recruit Count
- 120
- Registration Number
- NCT05708859
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance, California, United States
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 152
- Registration Number
- NCT05706506
- Locations
- 🇺🇸
Velocity Clinical Research, Huntington Park, Los Angeles, California, United States
🇺🇸Versailles Family Medicine, Versailles, Kentucky, United States
🇺🇸Texas Diabetes & Endocrinology, P.A., Austin, Texas, United States
A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT05696847
- Locations
- 🇺🇸
Atlanta Center of Medical Research, Atlanta, Georgia, United States
🇺🇸Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 257
- Registration Number
- NCT05691712
- Locations
- 🇨🇳
The Second People's Hospital of Hefei, Hefei, Anhui, China
🇨🇳The First Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳The First Affiliated Hospital of Henan University of Science &Technology, LuoyangShi, Henan, China
Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Ospedale San Raffaele
- Target Recruit Count
- 10
- Registration Number
- NCT05659368
- Locations
- 🇮🇹
IRCCS San Raffaele Scientific Institute, Milan, Italy
A Study of LY3457263 in Obese Participants
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 38
- Registration Number
- NCT05582096
- Locations
- 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 282
- Registration Number
- NCT05564039
- Locations
- 🇺🇸
Juno Research, Houston, Texas, United States
🇺🇸Biopharma Informatic, LLC, Houston, Texas, United States
🇷🇴Diabdana, Oradea, Bihor, Romania
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 15374
- Registration Number
- NCT05556512
- Locations
- 🇦🇹
Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna, Wien, Austria
🇧🇷CEPIC - Centro Paulista de Investigação Clínica, São Paulo, Brazil
🇲🇽Caimed Investigacion En Salud S.A. de C.V., Mexico City, Distrito Federal, Mexico
Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2022-09-23
- Target Recruit Count
- 150
- Registration Number
- NCT05553093
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.